Evaluation of Treatment Modalities of Egyptian Lymphoma Patients. Single Center Study

Abstract

Lymphoma is considered the most common hematologic malignancy in Egypt and accounts for about 8.4% of all new cancer cases annually. During the last decade the development of new drugs for the treatment of hematologic malignancies has come of age. In this study we aimed to evaluate the outcome of different treatment methodologies of lymphoma patients. In this study 74 Egyptian lymphoma patients with a mean age of 38.6 years (range 18-77 years) were included, 31 of which were diagnosed with Hodgkin’s lymphoma (group I), 10 with indolent NHL (subgroup IIa) and 33 patients with aggressive NHL (subgroup IIb). We studied the impact of different clinical and laboratory risk factors on the OS and DFS of enrolled patients. We also compared the different groups as regards clinical outcome and occurrence of complications. Hodgkin’s lymphoma patients represented (42%) of the whole patients, while NHL patients represented (58%) of patients. Regarding the male to female ratio, in Hodgkin’s lymphoma patients (group I), the male to female incidence ratio was (1.58:1). The mean age at presentation was (31.4 years) in HL (group I), which was lower than the other 2 groups, (50.9 years) in low grade NHL (subgroup IIa), (41.8 years) in high grade NHL (subgroup IIb), the younger age in group I was associated with less incidence of co-morbid conditions as DM, hypertension and ISHD. As regards association of HCV infection, the incidence among HL patients (group I) was (6%), and NHL patients (group II) was (18.6%) as detected by ELISA. None were found to be HBV positive among our patients.